Gutcultured®.
Clinically Proven.
Trusted Worldwide.
Every batch meets the world’s strictest standards for safety, stability and efficacy. Tested, certified and manufactured in Denmark.
Introducing LGG®
LGG® was first isolated from a healthy human intestine in 1985 by Drs. Goldin and Gorbach at Tufts University. In the four decades since, it has become the most clinically documented probiotic strain in published literature - not by marketing, but by accumulation of peer-reviewed evidence across populations, life stages, and health areas.
Also on this Page
BB-12® strain page | 90-Day Routine | Science overview
Not all strains are created equal.
A probiotic is only as good as its strains.
"Lactobacillus" or "Bifidobacterium" alone means nothing without the full strain name. Clinical research is strain-specific - not species-wide. Without the strain name, any health claims attached to that product are unattributable.
If you take one thing from this: Genus → Species → Subspecies → Strain name.
For Gutcultured, that is Lacticaseibacillus rhamnosus GG (LGG®) and Bifidobacterium animalis subsp. lactis (BB-12®).
There are dozens of recognised species within the Bifidobacterium genus alone - and many thousands of distinct strains across human, animal, and environmental niches. A single species name covers an enormous range of organisms with very different properties and evidence bases.
This is why strain specificity is not a technicality. It is the only basis on which probiotic science can be read, verified, or trusted.
Ask your provider for the full strain name and the specific research attached to it. → See our How to Choose a Probiotic Guide.
LGG® CLINICAL EVIDENCE
What the research documents.
LGG® has been studied across more life stages and health contexts than any other probiotic strain in the world. Here are seven health areas with published human evidence. The studies below represent published, peer-reviewed human research - not animal models or in vitro data, except where noted. Every claim is traceable to this specific named strain,
Preserving the gut lining under stress
RCT · HumanGut Barrier Function
Take-away: LGG® produces specific proteins that keep the gut lining sealed - stopping fragments that shouldn't be in your bloodstream from getting there. What people call "leaky gut" in normal conversation.
Details:
LGG® secreted proteins - specificallyp40 and p75 - preserve tight junction function and reduce intestinal permeability. In a translational model using human enteroids and colonoids, LGG® prevented IFN-γ-induced tight-junction disruption. A compromised gut barrier allows bacterial fragments (LPS) into systemic circulation. LGG® is researched specifically for its role in maintaining that barrier.
Han et al., 2019 · Gut Microbes · PMID 30040527 · Human enteroid/colonoid model
Gut comfort during and after antibiotics
RCT · Human Digestive Comfort · Antibiotic Use
Take-away: When antibiotics disrupt the gut, LGG® has been studied for over 30 years for its role in reducing the side effects - less loose stools, nausea, discomfort - that often follow a course of antibiotics.
Details:
LGG® has been studied in adults undergoing antibiotic treatment for its role in reducing antibiotic-associated gastrointestinal side effects - including loose stools, nausea, and taste disturbance.
Together, LGG® and BB-12® have been studied for improving treatment tolerance during H. pylori eradication therapy.
Armuzzi et al., 2001 · PMID 11148433 · Hauser et al., 2015 · PMID 25929897
Mucosal and systemic immune support
RCT · Human Immune Health
Take-away: In two separate trials, studies taking LGG® had fewer respiratory infections, fewer sick days, and fewer courses of antibiotics than those who didn't.
Details:
LGG® activates immune pathways viaTLR-2, TLR-6, and TLR-9, enhancing mucosal immunity. In daycare children, LGG® reduced the incidence and duration of upper respiratory tract infections vs placebo. In a 7-month RCT, children receiving LGG® showed consistent reductions in illness-related absences and complicated respiratory infections.
Hojsak et al., 2010 · PMID 19896252 · Hatakka et al., 2001 · PMID 11387176
Eczema risk reduction in high-risk infants
RCT · Human Dermatological Health
Take-away: In high-risk infants, LGG® taken during and after pregnancy reduced the incidence of eczema - and the effect held four years later.
Details:
In a perinatal RCT, LGG® supplementation reduced the incidence of atopic eczema in high-risk infants. The preventive effect persisted to age 4 in follow-up. The proposed mechanism involves early immune training — Th1/Th2 balance and regulatory T-cell modulation — during a critical developmental window.
Kalliomäki et al., 2001/2003 · PMID 11297958 / PMID 12788576 · RCT + 4-year follow-up
Cognitive performance research in adults
RCT · Preliminary Gut-Brain Axis · Cognition
Take-away: In one RCT, middle-aged adults taking LGG® showed measurable improvements in cognitive performance. Preliminary. Research ongoing.
Details:
Cognitive performance research in adultsIn a 2020 RCT (n=68, 12 weeks), researchers observed improved cognitive performance in middle-aged and older adults supplemented with LGG® versus placebo. The proposed mechanism is tryptophan/indole signalling - LGG® influences tryptophan metabolism, producing neuroactive compounds that interact with gut-brain signalling receptors. A 2022 follow-up in active healthy adults was neutral. Both findings are preliminary.The signal is consistent; the research is ongoing.
Sanborn et al., 2020 · PMID 33223831 · Sanborn et al., 2022 · PMID 35617704
Neurodevelopmental outcomes — 13-year follow-up
RCT Follow-up · PilotGut-Brain Axis · Neurodevelopment
Take-away: In a 13-year follow-up, none of the subjects who received LGG® in infancy were diagnosed with ADHD or ASD - versus 17% in the placebo group. Pilot scale. Not yet replicated. The effect size is remarkable.
Details:
A 13-year follow-up of an early LGG® RCT found that 0% of children in the LGG® group had received ADHD or ASD diagnoses at age 13, versus 17% in the placebo group. This is a pilot-scale finding (n=75 subset) and has not been replicated at scale. The effect size is extraordinary; the evidence base is preliminary. Researchers cite early microbial-immune-neurodevelopment programming as the proposed mechanism.
Pärtty et al., 2015 · PMID 25760553 · Pilot subset, not independently replicated
Tryptophan → Vitamin B3 metabolites
Mechanistic · Emerging Micronutrient Synthesis
Take-away: Early-stage research suggests LGG® may help convert tryptophan - the building block of serotonin - into compounds that support gut barrier protection. Preclinical. Research ongoing.
Details:
Emerging mechanistic research shows LGG® may stimulate the production of nicotinamide (vitamin B3) metabolites from dietary tryptophan — compounds linked in basic research to intestinal barrier protection and anti-inflammatory signalling. This is preclinical science. It informs understanding of how LGG® may work; it is not a validated clinical outcome.Suntornsaratoon et al., 2024 · PMID 38641207 · Preclinical + ex vivo model
From sachet to gut — what makes LGG® different
In vitro / Clinical Survivability & Adhesion
Take-away: Most bacteria pass through the gut without staying. LGG® has physical structures - pili - that grip the gut wall, letting it persist long enough to do what the research documents.
Details:
LGG® exhibits documented acid and bile tolerance - confirmed in simulated gastric conditions. Its SpaCBA pili structures enable strong adhesion to intestinal mucus and epithelial cells. In a clinical study, LGG® persisted longer and at higher levels in the human GI tract compared with a related L. rhamnosus strain that lacks pili. Pili integrity is maintained through the patented freeze-drying production process.
Kankainen et al., 2009 · PMID 19805152 · Tuomola & Salminen, 1998 · PMID 9493080
*What is an RCT? An RCT or Randomized Controlled Trial is considered the "gold standard" in clinical research because it isthe most reliable method for evaluating the safety and effectiveness of new treatments while minimizing bias. By randomly allocating participants into experimental or control groups, RCTs ensure balanced characteristics, allowing researchers to directly attribute outcome differences to the intervention itself.
Mechanism of Action
How LGG® works in the gut.
LGG® doesn't work through a single mechanism. The research documents at least four distinct pathways through which it interacts with the gut environment and - via the gut - with "upstream systems". These are not marketing descriptions. These are the mechanisms behind the clinical data above, and these are the documented modes of action cited in peer-reviewed literature.
Pathway 01 - Secreted proteins: p40 & p75
LGG® secretes two proteins - p40 and p75 - that prevent apoptosis (or death) of intestinal epithelial cells, increase mucus production, and decrease intestinal permeability. These are the proteins studied in barrier integrity research, including the Han et al. enteroid model.
Pathway 02 - Immunomodulation via TLR receptors
LGG®'s unique lipoteichoic acid structure interacts with TLR-2 and TLR-6 receptors. Unmethylated CpG-rich DNA from LGG® activates TLR-9, triggering a Th1 immune response that protects the epithelial layer. This is the pathway behind LGG®'s documented immune health research.
Pathway 03 - Pathogen inhibition
LGG® secretes antimicrobial substances that inhibit Salmonella, Shigella, Pseudomonas, Streptococcus, and Staphylococcus. It also competes with pathogenic bacteria for adhesion sites on the intestinal epithelium - a mechanism documented in both in vitro and clinical settings.
Pathway 04 - Tryptophan → indole signalling
LGG® influences tryptophan metabolism along the indole pathway, producing neuroactive compounds including indole-3-propionic acid. Tryptophan is the dietary precursor to serotonin. This is the proposed mechanism behind the Sanborn 2020 cognition research and the emerging gut-brain axis literature on LGG®.
LGG's pili structure - why it matters for everything above.
LGG® carries SpaCBA pili - hair-like structures on the cell surface that allow it to adhere firmly to intestinal mucus and epithelial cells. Without pili, LGG® cannot colonise effectively, cannot perform pathogen inhibition, and cannot maintain its barrier-protective function. Pili are not a marketing feature. They are the physical mechanism that determines whether the strain does anything at all once it reaches the gut.
In comparative clinical studies, LGG® persisted longer and at higher levels in the human GI tract than a related L. rhamnosus strain (Lc705) that lacks pili. The patented freeze-drying process is specifically designed to preserve pili structure through manufacture, storage, and transport. This is what the "until end of shelf life" claim is built on.
Genome verification in 2019 confirmed that LGG® is genomically identical to the original 1985 isolate - the strain all published LGG® research is based on. This matters because without genomic identity to the reference strain, any science claims from LGG® studies cannot be attributed to a different strain bearing the same name.
✪✪✪✪✪ 5 Stars from Verified Customers on Reviews.io
*Individual experiences vary. These are personal accounts and do not constitute health claims.
Start your 90-day routine
🎖 90-Day Confidence Guarantee: Applies to both the Rebalance (3 months, one-off) and the Lifestyle Subscription (4 months). If it doesn’t deliver, you keep the product and we refund your first month.
Questions
What people ask about LGG®.
Is LGG® the same in every product that claims to contain it?
No - and this is the most important thing to understand about strain claims. LGG® is a registered, licensed strain. Any product claiming to contain LGG® must use the licensed strain to make that claim validly. Products using generic Lactobacillus rhamnosus - without the registered GG designation - cannot attribute LGG® research to their strain.
In Gutcultured, the registered strain is Lacticaseibacillus rhamnosus GG, LGG®. The taxonomy is verifiable. The science is attributable.
How does LGG® survive stomach acid?
LGG® was specifically selected in 1985 for its exceptional acid and bile tolerance - this was one of the primary criteria in its isolation. It produces exopolysaccharides (EPS) - galactose-rich and glucose/mannose-rich polysaccharides - that act as survival adaptors through the GI tract. In simulated gastric conditions, LGG® retains viability.
The Gutcultured format - freeze-dried sachets - further protects the strain through manufacture and shelf life. Pili integrity, preserved through Novonesis' patented production process, is the mechanism that enables adhesion once the strain survives the journey.
What does "most documented" actually mean in practice?
It means the research is extensive, independently replicated, and publicly verifiable. Over 2,000 scientific publications and 300+ clinical studies - across newborns, children, adults, pregnant women, and the elderly - have been conducted on the specific LGG® strain. This is not a marketing number: it reflects decades of independent research by academic and clinical institutions globally. More documentation means more confidence in what the strain does, at what dose, in which populations. It also means more understanding of what it doesn't do - which is equally important for honest communication.
Can LGG® be taken with antibiotics?
Yes. LGG® was specifically studied in antibiotic contexts - this is one of its most documented health areas. In adults undergoing H. pylori triple therapy, LGG® reduced antibiotic-associated GI side effects including loose stools, nausea, and taste disturbance. It has been used alongside antibiotics in hospital settings for over 30 years. The documented acid and bile tolerance means LGG® survives the antibiotic regimen well enough to maintain gut presence. Timing - taking the probiotic a few hours away from the antibiotic dose - is generally recommended to maximise this.
Is the gut-brain axis research on LGG® reliable?
It is real science, and it is preliminary. The Sanborn 2020 RCT documented improved cognitive performance in at-risk middle-aged adults supplemented with LGG® (n=68, 12 weeks). The 2022 follow-up in active healthy adults was neutral. The Pärtty 2015 neurodevelopment follow-up is the most striking finding in the literature - 0% ADHD/ASD diagnoses at age 13 versus 17% in placebo - but it is a pilot-scale subset (n=75) and still needs to be replicated.
Gutcultured does not sell on this basis. We sell LGG® for its documented gut barrier and digestive regularity research. The gut-brain axis work is what the research community is investigating. The signal is consistent but the research is still ongoing.
LGG® is one of two precision strains in Gutcultured.
Paired with BB-12® - the world's most documented Bifidobacterium - at 10 billion CFU per sachet. Guaranteed until end of shelf life. One sachet a day, 90 days.
Researched for gut barrier support and digestive regularity in healthy adults.
🎖 The 90-Day Confidence Guarantee: Applies to both the Rebalance (3 months, one-off) and the Lifestyle Subscription (4 months). If it doesn’t deliver, you keep the product and we refund your first month.
✪✪✪✪✪ 5 Stars from Verified Customers on Reviews.io (English)
*Individual experiences vary. These are personal accounts and do not constitute health claims.